Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

774 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL).
Gobbi PG, Broglia C, Valentino F, Mammi C, Lombardo M, Merli F, Luminari S, Polimeno G, Riezzo A, Lambelet P, Rovati A, Corazza GR, Federico M; Gruppo Italiano Studio Linfomi. Gobbi PG, et al. Among authors: federico m. Ann Oncol. 2006 Apr;17(4):676-82. doi: 10.1093/annonc/mdl002. Epub 2006 Jan 30. Ann Oncol. 2006. PMID: 16446317 Free article. Clinical Trial.
ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL).
Silingardi V, Federico M, Cavanna L, Avanzini P, Gobbi PG, Lombardo M, Carotenuto M, Frassoldati A, Pieresca C, Vallisa D, et al. Silingardi V, et al. Among authors: federico m. Leuk Lymphoma. 1995 Apr;17(3-4):313-20. doi: 10.3109/10428199509056837. Leuk Lymphoma. 1995. PMID: 8580801 Clinical Trial.
Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience.
Gobbi PG, Pieresca C, Frassoldati A, Carotenuto M, Di Renzo N, La Sala A, Berté R, Avanzini P, Federico M, Silingardi V, Ascari E. Gobbi PG, et al. Among authors: federico m. J Clin Oncol. 1996 Feb;14(2):527-33. doi: 10.1200/JCO.1996.14.2.527. J Clin Oncol. 1996. PMID: 8636767 Clinical Trial.
CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Gobbi PG, Pieresca C, Cavanna L, Corbella F, Vallisa D, Federico M, Formisano R, Carotenuto M, Merli F, Callea V, Angrilli F, Silingardi V. Gobbi PG, et al. Among authors: federico m. Haematologica. 1996 Nov-Dec;81(6):503-12. Haematologica. 1996. PMID: 9009437 Free article. Clinical Trial.
A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Baldini L, Guffanti A, Gobbi P, Colombi M, Federico M, Avanzini P, Cavanna L, Pieresca C, Silingardi V, Maiolo AT. Baldini L, et al. Among authors: federico m. Cancer. 1997 Mar 15;79(6):1234-40. doi: 10.1002/(sici)1097-0142(19970315)79:6<1234::aid-cncr24>3.0.co;2-#. Cancer. 1997. PMID: 9070503
Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Merli F, Federico M, Avanzini P, Ilariucci F, Stelitano C, Iannitto E, Colombi M, Vallisa D, Santagati G, Picinini L. Merli F, et al. Among authors: federico m. Haematologica. 1998 Mar;83(3):217-21. Haematologica. 1998. PMID: 9573675 Free article. Clinical Trial.
774 results